炎症性肠病患者临床分析  

作　　者：季雪良[1] 陈光兰[1] 汪望月[1] 潘文胜[2] 张晔[1] 王昌雄[1] 

机构地区：[1]浙江省丽水市人民医院,323000 [2]浙江大学医学院附属第二医院,310009

出　　处：《浙江临床医学》2017年第1期98-99,102,共3页Zhejiang Clinical Medical Journal

摘　　要：目的：探讨炎症性肠病（IBD）住院患者的诊断与治疗，为临床诊治提供借鉴。方法2010年1月至2015年9月67例首发初治的炎症性肠病患者临床资料，分析其临床特点、实验室检验、内镜下表现、药物治疗及治疗效果。结果67例炎症性肠病患者，其中溃疡性结肠炎（UC）54例，克罗恩病（CD）13例，采取以美沙拉嗪抗炎为主的综合治疗，47例UC与9例CD患者经治疗后在临床表现、实验室检验和（或）内镜下表现均有效好转，治疗有效率UC为87.04%，CD为69.23%，总有效率为83.58%；另有7例UC、4例CD患者无明显改善，其中1例CD患者转外科手术治疗。结论 IBD患者多为首发初治，经过正规治疗后病情多能有效缓解，以美沙拉嗪为主的综合治疗在临床应用上有良好效果。ObjectiveTo investigate the diagnosis and treatment of the inflammatory bowel disease（IBD）hospitalized patients and provide a reference for clinical diagnosis and treatment.MethodsFrom January 2010 to September 2015 in our hospital clinical data of 67 newly diagnosed IBD patients were retrospectively analyzed. In all the patients the clinical features,laboratory tests,endoscopic features,medication and treatment were summarized.ResultsOf 67 cases of IBD patients 54 cases were ulcerative colitis（UC）and 13 cases were Crohn＇s disease（CD）;After taking anti-inflammatory therapy（mesalazine）,clinical manifestations,laboratory testing,and（or）endoscopic findings in 47 UC patients and 9 CD patients were effectively improved;The total efficiency of UC was 87.04%,CD 69.23%,with a total effective rate of 83.58%;Another 7 UC patients and 4 CD patients had no significant improvement;One CD patients transferred to surgery.Conclusion IBD patients all have the first treatment;After more scientific rules treatment of the disease patients can have effective relieve,Mesalazine combined therapy in clinical applications has good results.

关 键 词：炎症性肠病 溃疡性结肠炎 克罗恩病 美沙拉嗪 

分 类 号：R574[医药卫生—消化系统]